Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
News and Events

Featured Stories

Hot information:
Top 10 Global CDMO Enterprises| Top 10 Global Clinical Research Organizations in 2021| The Meaning of IND, NDA and ANDA
Aug 20,2015
Jumping Genes May Play An Important Role in GI Cancers
    Gastrointestinal cancer (GI cancer) refers to malignant conditions of the gastrointestinal tract (GI tract) and accessory organs of digestion, including the esophagus, stomach, biliary system, pancreas, small intestine, large intestine, rectum and anus.  The studies state that a jumping gene may play a critical role in the GI cancer.         Results of a trio ofRead more
More
Jumping Genes May Play An Important Role in GI Cancers
Aug 19,2015
Adhesion Protein Plays Double Agent, Key Role in Cell Migration
If you've ever been on the receiving end of a good pinch, you're probably well aware of how much they can hurt, but perhaps a little less cognizant of the molecular mechanisms that prevent your skin detaching from the body. The mechanics at the cellular level that provide this protection are not only fascinating, butRead more
More
Adhesion Protein Plays Double Agent, Key Role in Cell Migration
Aug 19,2015
Novel Enzyme Finding Points Way to Improved Cognitive Therapies
    An international scientific team altered a gene in mice to inhibit the activity of phosphodiesterase-4B (PDE4B), which is present in many organs of the vertebrate body, including the brain. In behavioral tests, the PDE4B-inhibited mice showed enhanced cognitive abilities. They tended to learn faster, remember events longer, and solve complex exercises better than ordinary mice.Read more
More
Aug 18,2015
DNA-Vitamin E Complex Works as Potent Gene Silencer
    Gene silencing is an effective method for turning down or off the aberrant genetic message that leads toward disease phenotypes. Therapeutics that takes advantage of this technology are beginning to enter the market. However, opportunities still remain for improving the efficient delivery of nucleic acid drugs to the relevant diseased tissues.       Now, a teamRead more
More
Aug 18,2015
Engineering Therapeutic Proteins into Antibodies
    Scientists at the Scripps Research Institute (TSRI) have devised an improved method for building proteins into larger proteins such as antibodies. The new technique mimics evolution by generating millions of possible junction segments between the inserted protein and its antibody host, selecting the rare ones that allow the inserted protein to fold and function normally.Read more
More
Aug 17,2015
Roche to Acquire GeneWEAVE for Up-to $425M
    Roche said it plans to acquire GeneWEAVE for up to $425 million, in a deal intended to strengthen its offerings in clinical microbiology diagnostics.     Through the acquisition, Roche said, it will be better able to fight drug-resistant bacteria because it will own GeneWEAVE's Smarticles™ technology. Smarticles is a class of molecular diagnostics designed to quicklyRead more
More
Aug 17,2015
DNA Repair Genes May Determine When Huntington Symptoms Begin
    A research team that searched the chromosomes of more than 4,000 Huntington’s disease patients reports that they found that DNA repair genes may determine when the neurological symptoms begin. The scientists believe the results may provide a guide for discovering new treatments for Huntington’s disease and a roadmap for studying other neurological disorders.     “Our hopeRead more
More
Aug 14,2015
Jackson Laboratory Launches Precision Genetics Center with $10M NIH Grant
    The Jackson Laboratory (JAX) will partner with several collaborating institutions to establish a new Center for Precision Genetics, to be launched through a five-year, $9,971,936 grant from the NIH. The new center will work toward the goal of finding solutions for life-threatening and genetically complex human diseases through new approaches to developing precision models ofRead more
More
Aug 14,2015
MedImmune Licenses Inovio Cancer Vaccine for Up-to $727.5M
    AstraZeneca's MedImmune subsidiary will acquire exclusive rights to Inovio Pharmaceuticals' Phase I/II INO-3112 immunotherapy, which targets cancers caused by human papillomavirus (HPV) types 16 and 18, the companies said today. MedImmune and Inovio will also collaborate to develop up to two more cancer vaccine candidates under a license agreement and collaboration that could generate upRead more
More
MedImmune Licenses Inovio Cancer Vaccine for Up-to $727.5M
Aug 13,2015
To Kill Cancer, Do Not Repress It, Excite It
    The momentum of a cancer's attack can be used against the cancer, say scientists who practice a form of molecular judo. Instead of directly blocking the action of cancer-causing genes, the scientists use this action against cancer cells, throwing them off balance. Committed to a super-stimulated state, cancer genes can't help but generate a super-abundanceRead more
More
To Kill Cancer, Do Not Repress It, Excite It